Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Bad CME" Program May Be Developed By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency asks physicians to report instances of off-label promotion made during continuing medical education classes.
Advertisement

Related Content

Can Bad Ad Program's Light Penetrate Murky CME, Clinical Trial Practices?
Can Bad Ad Program's Light Penetrate Murky CME, Clinical Trial Practices?
DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling
DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling
Off-Label Use Of Malaria Drug Drives FDA To Impose REMS
Off-Label Use Of Malaria Drug Drives FDA To Impose REMS
Separate FDA Post-Market Drug Safety Office Outlined In Approps Bill Report
Separate FDA Post-Market Drug Safety Office Outlined In Approps Bill Report
FDA Deputizes Doctors In Hunt For "Bad Ads"
FDA Deputizes Doctors In Hunt For "Bad Ads"

Topics

Advertisement
UsernamePublicRestriction

Register

PS070809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel